CION Ameerpet
Stage 3 means disease has spread beyond the pelvis within the abdomen. It is the commonest stage at which ovarian cancer is diagnosed, and — this is the part that gets lost — it is treated with the intent of achieving remission, not merely controlling disease.
Ovarian cancer stages describe how far disease has travelled, not how aggressive it is — that is what grade describes, and the two are separate. Stage 3 means the cancer has spread beyond the pelvis to the peritoneal surfaces within the abdomen, or to lymph nodes at the back of the abdomen, while remaining inside the abdominal cavity.
That boundary matters. Ovarian cancer spreads primarily by shedding cells across the peritoneum — the membrane lining the abdominal cavity — which is why it reaches stage 3 relatively readily and why it is the commonest stage at diagnosis. But disease that is still within that cavity remains reachable by surgery in a way that stage 4 disease outside it is not.
This is why stage 3 is treated with the intent of achieving remission. Surgery aims to remove all visible disease, and chemotherapy treats what cannot be seen. Most stage 3 ovarian cancer is high-grade serous, which is typically the most chemo-sensitive subtype. It is serious, and it is genuinely treatable, and both halves of that belong in the same sentence.
How far disease has spread. Grade describes how abnormal the cells are, and the two are separate.
Spread across the peritoneum, but not beyond the abdominal cavity — which keeps surgery in play.
Surgery to remove all visible disease plus chemotherapy this subtype usually responds well to.
In stage 3 ovarian cancer, the single strongest influence on outcome is whether all visible disease can be removed at surgery — complete cytoreduction. Women who finish surgery with no visible residual disease do substantially better than those left with even small deposits. This is why who performs the operation matters so much: outcomes are consistently better where staging and debulking are done by a specialist gynaecologic-oncology surgeon working in a centre that does them regularly. It is entirely reasonable to ask, before your operation, who will be performing it and what they expect to achieve. Source: NCCN Ovarian Cancer guidelines; published cytoreduction outcome data.
Stage 3 is subdivided by how extensive the peritoneal spread is. Your report will name one of these.
| Substage | What it describes | Practical significance |
|---|---|---|
| IIIA1 | Spread to retroperitoneal lymph nodes only, confirmed microscopically. | The least extensive stage 3. Peritoneal surfaces are not visibly involved. |
| IIIA2 | Microscopic peritoneal spread beyond the pelvis, with or without nodes. | Deposits too small to see, found only on examining sampled tissue. |
| IIIB | Visible peritoneal deposits beyond the pelvis, 2 cm or smaller. | Visible disease, but limited in size. Complete removal is often achievable. |
| IIIC | Visible peritoneal deposits beyond the pelvis larger than 2 cm, or involving liver or spleen surface. | The most extensive stage 3, and the commonest substage at diagnosis. |
*Deposits on the surface of the liver or spleen remain stage 3, because the surface is peritoneal. Disease inside the liver itself is stage 4 — a distinction that matters and is easily misread.
Surgery and chemotherapy together, with the order determined by whether complete removal looks achievable at the outset.
The aim is removing all visible disease. In practice this usually means removing both ovaries and tubes, the uterus, the omentum, and any peritoneal deposits — sometimes including stripping peritoneal surfaces or removing a segment of bowel where disease involves it. It is major surgery and it is where the greatest single influence on outcome lies.
Outcomes are consistently better where this is performed by a specialist gynaecologic-oncology surgeon. At CION this surgery is coordinated with specialist partner centres and may be billed there — arranged that way precisely because specialist surgery matters here. See debulking surgery.
Where the CT suggests all visible disease can be removed at the outset, primary surgery followed by chemotherapy is usually preferred. Where disease is too extensive for complete removal upfront, chemotherapy is given first to shrink it — neoadjuvant chemotherapy — with interval debulking surgery following.
Neither route is second best. Both are well evidenced in their own circumstances, and the imaging is largely what determines which one applies to you. If you are on the chemotherapy-first pathway, that reflects what the scan showed rather than any judgement about how treatable your disease is.
The backbone of treatment, typically given over several cycles. Most stage 3 ovarian cancer is high-grade serous, which is typically the most chemo-sensitive of the subtypes — response is frequently substantial and often visible early through a falling CA-125 and reducing ascites.
Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, so treatment can continue near where you live rather than requiring repeated travel while you are unwell.
After first-line chemotherapy, maintenance therapy aims to extend the period before disease returns. PARP-inhibitor-class drugs are the principal option and their benefit is greatest where the tumour has impaired DNA repair — which applies to roughly half of high-grade serous cancers.
This is why BRCA and HRD testing matter at this stage: they determine whether the option applies to you. Both are delivered in-house at CION, as is the maintenance treatment. If neither has been done, ask. See HRD testing.
Because stage 3 disease sits on the peritoneal surfaces, treatment delivered directly into the abdominal cavity has a logic to it. Intraperitoneal chemotherapy and heated intraperitoneal chemotherapy given at the time of surgery are used in selected situations.
These are specialised techniques with specific indications rather than routine options, and whether they apply is a tumour-board decision. At CION they are coordinated with specialist gynaecologic-oncology partner centres and may be billed there.
Stage 3 disease frequently causes ascites and early satiety, which makes eating difficult exactly when nutrition matters most for tolerating treatment. Weight loss before and during chemotherapy affects how well treatment is managed and how many cycles can be completed.
CION patients on the supported nutrition pathway experience 67% less weight loss during treatment. Dietetic input from the start, rather than once problems appear, makes a measurable difference. See nutrition support.
These are the ones that most affect what happens, and several are frequently not covered unless asked.
Complete cytoreduction is the strongest single influence on outcome. A specific question with a specific answer.
Outcomes are consistently better with a specialist gynaecologic-oncology surgeon. Entirely fair to ask.
Ask what the CT showed and why that route was chosen. Neither is second best.
Both are standard at this stage and both determine whether maintenance therapy applies to you.
PARP-inhibitor-class treatment after chemotherapy. If not mentioned, ask why.
It describes how extensive the peritoneal spread is and feeds into the surgical plan.
Ask about nutrition early rather than once eating becomes difficult. Weight loss during treatment affects how many cycles can be completed.
The aim is remission. Surgery to remove all visible disease and chemotherapy that this subtype usually responds well to are a genuine combination, not a holding measure.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres.
Everyone diagnosed at this stage looks up survival figures, and the numbers found online mislead in specific and predictable ways that are worth understanding before you read them.
They are historical, describing women treated years ago — before PARP-inhibitor-class maintenance therapy, before routine HRD testing, and before current surgical standards for complete cytoreduction. They are averages across whole populations, mixing substages, subtypes, ages and levels of general health. And critically for stage 3, they mix together women who achieved complete surgical removal with those who did not, when that single factor makes a substantial difference.
CION publishes its own one-year survival alongside the national figure so the comparison is visible: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That is across all stages rather than stage-specific, and it is a one-year figure rather than a cure rate. Your own outlook depends on your substage, on whether complete removal was achieved, on how the disease responds to platinum, and on your general health — which is a conversation for your oncologist, who can speak to your actual situation.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population, all stages.
The comparable national figure. *One-year survival; national registry data, all stages.
They describe women treated before maintenance therapy and routine HRD testing existed.
A factor that makes a substantial difference at stage 3, averaged away in a single number.
*One-year survival rates across all stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own prognosis with your treating oncologist.
A stage 3 diagnosis usually arrives alongside a great deal of other information, at a point when very little is being absorbed. Women commonly leave knowing the word advanced was used and almost nothing about what the plan is or what it is trying to achieve.
Your first consultation at CION is free and runs to about 45 minutes. Bring your pathology report and imaging. Much of the useful work is establishing what the plan is, what it aims for, and — the question people find hardest to ask — who will be doing the surgery, since that matters more at this stage than at almost any other.
We should be clear about the division. Chemotherapy and PARP-inhibitor-class maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, as are genetic counselling, BRCA and HRD testing, and nutrition support. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — arranged that way because specialist surgery genuinely improves outcomes here. Every case goes to a tumour board.
Free and unhurried. Long enough to establish what the plan is and what it is trying to achieve.
Multidisciplinary review — medical oncology, imaging and pathology — before a plan is set.
Cytoreduction at specialist gynaecologic-oncology partner centres, and may be billed there. Stated upfront.
CION patients on the supported nutrition pathway, which affects how well treatment is tolerated.
It means the cancer has spread beyond the pelvis to the peritoneal surfaces within the abdomen, or to lymph nodes at the back of the abdomen, while remaining inside the abdominal cavity. Stage describes how far disease has travelled, not how aggressive it is — that is what grade describes, and they are separate. Stage 3 is the commonest stage at which ovarian cancer is diagnosed, because the disease spreads by shedding cells across the peritoneum and reaches this stage relatively readily. Disease still within the abdominal cavity remains reachable by surgery, which is why it is treated with the intent of achieving remission.
It is treated with the intent of achieving remission rather than merely controlling disease, and many women do achieve it. The honest position is that recurrence is common at this stage, so long-term outcomes vary considerably — but remission is a realistic aim rather than an optimistic one. Two things influence it most: whether all visible disease can be removed at surgery, and how well the disease responds to platinum-based chemotherapy. Most stage 3 ovarian cancer is high-grade serous, which is typically the most chemo-sensitive subtype. Your oncologist can speak to your particular situation.
They describe how extensive the spread beyond the pelvis is. IIIA1 means spread to retroperitoneal lymph nodes only, confirmed microscopically. IIIA2 means microscopic peritoneal spread beyond the pelvis, found only on examining sampled tissue. IIIB means visible peritoneal deposits beyond the pelvis measuring 2 cm or smaller. IIIC means visible deposits larger than 2 cm, or involvement of the liver or spleen surface, and is the commonest substage at diagnosis. Deposits on the surface of the liver remain stage 3; disease inside the liver itself is stage 4.
Because in stage 3 ovarian cancer the single strongest influence on outcome is whether all visible disease can be removed — complete cytoreduction. Women who finish surgery with no visible residual disease do substantially better than those left with even small deposits. Achieving that requires experience, and outcomes are consistently better where staging and debulking are performed by a specialist gynaecologic-oncology surgeon working in a centre that does them regularly. It is entirely reasonable to ask before your operation who will perform it and what they expect to achieve.
Because your imaging suggested that complete removal of all visible disease was not achievable at the outset. In that situation, giving chemotherapy first to shrink the disease — neoadjuvant chemotherapy — followed by interval debulking surgery gives a better chance of achieving complete removal than operating immediately would. This is a well-evidenced route rather than a lesser option, and it reflects what the CT showed rather than any judgement about how treatable your disease is. Ovarian cancer is frequently platinum-sensitive, and substantial responses to that initial chemotherapy are common.
It depends on your tumour's characteristics, which is why BRCA and HRD testing matter at this stage. After first-line chemotherapy, maintenance therapy aims to extend the period before disease returns, and PARP-inhibitor-class drugs are the principal option. Their benefit is greatest where the tumour has impaired homologous recombination DNA repair, which applies to roughly half of high-grade serous cancers. Without testing, that option is never raised. Both the testing and the maintenance treatment are delivered in-house at CION — if neither has been discussed with you, it is worth asking.
Read them carefully. They are historical, describing women treated before PARP-inhibitor-class maintenance therapy, routine HRD testing and current surgical standards for complete cytoreduction existed. They are averages mixing substages, subtypes, ages and general health together. And critically for stage 3, they mix women who achieved complete surgical removal with those who did not — a factor that makes a substantial difference and is averaged away in a single number. CION reports 81.0% one-year survival across all stages against a national 73.7%, but even that describes a group rather than a person.
The first consultation is free and runs to about 45 minutes — bring your pathology report and imaging. Chemotherapy and PARP-inhibitor-class maintenance therapy are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, as are genetic counselling, BRCA and HRD testing, and nutrition support, where patients on the supported pathway experience 67% less weight loss during treatment. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — arranged that way because specialist surgery genuinely improves outcomes at this stage.